Money Control Place
  • Politics
  • Business
  • Stocks
  • Investing
  • Politics
  • Business
  • Stocks
  • Investing

Money Control Place

Politics

FDA declines approval for Amneal Pharmaceuticals’ Parkinson’s drug

by July 4, 2023
July 4, 2023
FDA declines approval for Amneal Pharmaceuticals’ Parkinson’s drug

The U.S. Food and Drug Administration (FDA) has declined to approve Amneal Pharmaceuticals’ drug for Parkinson’s disease due to inadequate safety data on the treatment to help control symptoms in patients for a longer duration, the company said on Monday.

Shares of Amneal Pharmaceuticals fell 13.1% to $2.7 in choppy after-market trading.

The FDA in a complete response letter said while the company established the safety of one ingredient, levodopa, based on some studies, it was not able to adequately establish safety for the other ingredient, carbidopa.

The health regulator has requested additional information on the safety of the drug, while it did not identify any efficacy or manufacturing issues with the drug.

Amneal’s drug is a new formulation of carbidopa-levodopa, the standard of care for Parkinson’s, and is designed in a way that allows it to remain in a certain area of the small intestine for a longer period, helping in its consistent absorption.

The company said it will work closely with the health regulator to address the issues and plans to meet with the agency.

The health regulator’s decision is a potential hurdle to the company, which has been looking to grow its portfolio of branded drugs, expecting over $500 million in revenues from its specialty business by 2027.

The drugmaker said the decision does not impact its 2023 financial forecast as it did not include the revenue from the drug.

Amneal currently has another Parkinson’s drug, Rytary, which was approved in 2015 in the market but had been struggling to gain a foothold in the treatment space, with only 4% of patients using it.

Parkinson’s is a brain disorder that causes unintended or uncontrollable movements and is the second most-deadly neurodegenerative disease after Alzheimer’s. There is no cure for Parkinson’s currently, but medicines and other therapies can help relieve symptoms.

<!–>

This post appeared first on FOX NEWS

–>

0
FacebookTwitterGoogle +Pinterest
previous post
Georgia universities spent millions on DEI efforts prior to state budget cuts: Report
next post
NRA slaps Biden admin with lawsuit over ‘unlawful’ pistol brace rule

Related Posts

New York Gov. Kathy Hochul considers ban on...

July 20, 2023

House Republican says he opposes all temporary government...

August 22, 2023

After Pence ends 2024 bid, GOP insiders predict...

October 29, 2023

DOD casts doubt on Iran-backed militia’s claim to...

January 31, 2024

McConnell in talks to endorse Trump in 2024...

March 6, 2024

Biden hosts anti-Israel world leader to talk climate,...

November 2, 2023

Biden says debating Trump ‘depends on his behavior’

March 9, 2024

Sullivan rips reporter’s question on Biden swearing as...

March 19, 2024

House Republicans heap praise on Taiwan’s new leader...

January 26, 2024

Maine Democratic Gov. Janet Mills vetoes bill aimed...

July 20, 2023

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • The NASDAQ 100, On The Brink Of A Breakout, Needs Help From This Group

    • Tech 5: OpenAI/Microsoft Talks Get Tense, SoftBank Floats Arizona Robotics Hub

    • Editor’s Picks: Silver Price Hits 13 Year High, Gold Takes a Breather

    • Joe Rabil’s Undercut & Rally Pattern: From DROP to POP

    • RRG Alert Tech Vaults to ‘Leading’—Is XLK Signaling a New Rally?

    • Coelacanth Energy

    Categories

    • Business (1,259)
    • Investing (2,585)
    • Politics (3,699)
    • Stocks (1,670)
    • Uncategorized (20)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: MoneyControlPlace.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 moneycontrolplace.com | All Rights Reserved